title: Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.
authors.affiliation: Melanoma Disease Center of Dana-Farber Cancer Institute; Brigham and Women's Hospital and Harvard Medical School, Boston, MA jason_luke@dfci.harvard.edu.
authors.forename: Jason J
authors.initials: JJ
authors.lastname: Luke
authors.affiliation: Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Lezcano
authors.affiliation: Melanoma Disease Center of Dana-Farber Cancer Institute; Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.affiliation: Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
authors.forename: George F
authors.initials: GF
authors.lastname: Murphy
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000276:immunology; D006099:Granuloma / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab